Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience

Christopher J Lehmann; Mai T Pho; David Pitrak; Jessica P Ridgway; Natasha N Pettit

doi:10.1093/cid/ciaa902

Community-acquired Coinfection in Coronavirus Disease 2019: A Retrospective Observational Experience

Clin Infect Dis. 2021 Apr 26;72(8):1450-1452. doi: 10.1093/cid/ciaa902.

Authors

Christopher J Lehmann¹, Mai T Pho¹, David Pitrak¹, Jessica P Ridgway¹, Natasha N Pettit²

Affiliations

¹ Section of Infectious Disease and Global Health, Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.
² Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois, USA.

Abstract

Community-acquired coinfection in coronavirus disease 2019 (COVID-19) is not well defined. Current literature describes coinfection in 0-40% of COVID-19 patients. In this retrospective report, coinfection was identified in 3.7% of patients and 41% of patients admitted to intensive care (P < .005). Despite infrequent coinfection, antibiotics were used in 69% of patients.

Keywords: COVID-19; SARS-CoV-2; antibiotics; coinfection; superinfection.

MeSH terms

COVID-19*
Coinfection* / epidemiology
Hospitalization
Humans
Retrospective Studies
SARS-CoV-2